Pulmonary Hypertension Clinical Trial
— PinCOfficial title:
Physiological-based Cord Clamping Versus Immediate Cord Clamping for Infants Born With Congenital Diaphragmatic Hernia: a Multicentre, Randomised Controlled Trial
Pulmonary hypertension is a major determinant of postnatal survival in infants with a congenital diaphragmatic hernia (CDH). The current care during the perinatal stabilisation period in infants born with this rare birth defect might contribute to the development of pulmonary hypertension after birth - in particular umbilical cord clamping before lung aeration. An ovine model of diaphragmatic hernia demonstrated that cord clamping after lung aeration, called physiological-based cord clamping (PBCC), avoided the initial high pressures in the lung vasculature while maintaining adequate blood flow, thereby avoiding vascular remodelling and aggravation of pulmonary hypertension. The investigators aim to investigate if the implementation of PBCC in the perinatal stabilisation period of infants born with a CDH could reduce the incidence of pulmonary hypertension in the first 24 hours after birth. The investigators will perform a multicentre, randomised controlled trial in infants with an isolated CDH. Before birth, infants will be randomised to either PBCC or immediate cord clamping, stratified by treatment centre and severity of pulmonary hypoplasia on antenatal ultrasound. For performing PBCC a purpose-designed resuscitation module (the Concord Birth Trolley) will be used.
Status | Recruiting |
Enrollment | 140 |
Est. completion date | July 1, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Weeks and older |
Eligibility | Inclusion Criteria: - Left-sided CDH - Isolated CDH: no associated structural or genetic abnormalities that are diagnosed before birth - Gestational age at delivery =35.0 weeks - Parental written informed consent Exclusion Criteria: - Right-sided or bilateral CDH - Gestational age at delivery <35.0 weeks - Maternal contraindications: anterior placenta praevia, placental abruption - High urgency caesarean section, with intended interval to delivery <15 min - Cases that have been treated during pregnancy with experimental drug therapy aiming to decrease the occurrence of pulmonary hypertension - Twin pregnancies in which the infant diagnosed with a CDH is born first - Multiple birth >2 (triplets or higher order) |
Country | Name | City | State |
---|---|---|---|
Australia | Monash University | Melbourne | |
Austria | Medical University Graz | Graz | |
Belgium | University Hospitals leuven | Leuven | |
Germany | Universitätskrankenhaus Bonn | Bonn | |
Germany | Universitätsklinik Mannheim | Mannheim | |
Italy | Ospedale Pediatrico Bambino Gesu | Rome | |
Netherlands | Radboudumc University Medical Center | Nijmegen | |
Netherlands | Erasmus MC University Medical Center - Sophia Children's Hospital | Rotterdam | |
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center |
Australia, Austria, Belgium, Germany, Italy, Netherlands, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with pulmonary hypertension diagnosed in the first 24 hours after birth. | Pulmonary hypertension is present if at least 2 of the following 4 criteria are present or if the infant requires extracorporeal membrane oxygenation (ECMO) in the first 24 hours after birth:
Right ventricular systolic pressure (RVSP) =2/3 systemic systolic pressure* Right ventricle (RV) dilatation/septal displacement or RV dysfunction +/- left ventricle (LV) dysfunction* Pre-post ductal SpO2 difference >10% for at least 15 consecutive minutes Oxygenation Index >20** *as found on first ultrasound in first 24 hours after birth; **highest value measured in first 24 hours after birth The following echocardiographic parameters will be collected to objectify these criteria: RV size Pulmonary artery acceleration time (PAAT), right ventricular ejection time (RVET), PAAT:RVET ratio Intraventricular septum configuration LV systolic eccentricity index Mean airway pressure PaO2 FiO2 Preductal+postductal SpO2 |
First 24 hours after birth | |
Secondary | Neonatal: mortality before discharge from the tertiary care hospital | Number of patients that died before discharge | From birth till discharge from the tertiary care hospital, through study completion an average of one year | |
Secondary | Neonatal: presence of 3 or more criteria for pulmonary hypertension or extracorporeal membrane oxygenation within 24 hours after birth | Number of patients with 3 or more criteria or ECMO | The first 24 hours after delivery | |
Secondary | Neonatal: number of patients requiring ECMO therapy | Number of patients requiring ECMO therapy | From admission to the ICU until the date of death or the date of discharge home, whichever came first | |
Secondary | Neonatal: number of days of duration of supplemental oxygen need | Number of days of duration of supplemental oxygen need | From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year | |
Secondary | Neonatal: number of days of duration of mechanical ventilation | Number of days of duration of mechanical ventilation | From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year | |
Secondary | Neonatal: duration of admission to the tertiary care hospital | Number of days of admission to the tertiary care hospital | From admission to the ICU until the date of discharge to another ward or home, whichever came first | |
Secondary | Maternal: number of patients with postpartum haemorrhage | Postpartum haemorrhage is defined as estimated blood loss >1000 mL | The first 24 hours after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A |